Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis

Using Artificial Intelligence to Reduce Gadolinium Contrast

This article orginally ran as an introduction to the Contrast Media Injectors comparison chart in the April 2019 issue. You can view the chart here

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

One of the most controversial issues in radiology in recent years has been the use of gadolinium as a contrast agent in magnetic resonance imaging (MRI) exams. Some studies and high-profile cases have suggested trace amounts of gadolinium are retained in the body after an exam and may cause a number of side effects, including nephrogenic systemic fibrosis (NSF) in the kidneys. A recent study out of Stanford University demonstrated how the need for gadolinium contrast could be reduced or eliminated by using artificial intelligence (AI)-based image reconstruction.

“There is concrete evidence that gadolinium deposits in the brain and body,” said study lead author Enhao Gong, Ph.D. “While the implications of this are unclear, mitigating potential patient risks while maximizing the clinical value of the MRI exams is imperative.”

Gong and colleagues created a deep learning algorithm, a form of AI, to analyze MRI datasets. With deep learning, a computer algorithm is shown large amounts of data and learns to recognize patterns and features in an image. The goal in radiology is for the computer to be able to identify critical findings in an image more or as quickly as a human radiologist.

For this particular study, the algorithm was shown MR images from 200 patients who had received contrast-enhanced MRI scans for a variety of indications. Three sets of images were collected for each patient:

•    Pre-contrast scans, done prior to contrast administration and referred to as the zero-dose scans;

•    Low-dose scans, acquired after 10 percent of the standard gadolinium dose administration; and

•    Full-dose scans, acquired after 100 percent dose administration.

Using this methodology allowed the algorithm to learn the difference between full- and low-dose administration, with the pre-contrast scans used as a control. With this knowledge at hand, the algorithm was able to reconstruct an image as if it was a full-dose scan from a 10 percent dose image. Study results showed there was no significant difference between an actual full-dose image and a reconstructed full-dose image.

Gong and colleagues said their study results indicate that eventually, the need for full dose gadolinium contrast could be eliminated. “Low-dose gadolinium images yield significant untapped clinically useful information that is accessible now by using deep learning and AI,” he said.

Equally important as the research findings themselves was validating the outputs of the algorithm, because radiologists need to be able to trust the results they are receiving. The research team employed quantitative metrics to evaluate the improvement of the enhanced contrast via deep learning, including peak signal-to-noise ratio (PSNR), root mean square error (RMSE) and structural similarity index (SSIM). Qualitative metrics like image quality and contrast enhancement quality were used to assess the results of the deep learning-based enhancement. A non-inferiority test was used to assess the performance of the AI method and validate the ability to reduce contrast dose without sacrificing image quality. “We showed that it’s doing a certain type of enhancement or denoising on the subtraction level. But the subtraction is not done manually because the algorithm learns how to do subtraction and enhancement. So the signal was already in there, but the human eye cannot see the difference — but the algorithm can,” said Gong.

The next steps involve deploying the algorithm in a clinical setting, where Gong believes it will see its greatest utility. He said the algorithm will be tested across a wider range of MRI scanners, and even with other contrast agents besides gadolinium. “We’re not trying to replace existing imaging technology,” he said. “We’re trying to improve it and generate more value from the existing information while looking out for the safety of our patients.”

Gong received a Radiological Society of North America (RSNA) “Trainee Research Prize — Resident” award for his research, which was presented at the RSNA 2018 annual meeting last November.

 

Related Content of MRI Gadolinium Safety Concerns

The Debate Over Gadolinium MRI Contrast Toxicity

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

Recent Developments in Contrast Media

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

European Medicines Agency Issues Update on Gadolinium Contrast Agents

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

FDA: No Harm in MRI Gadolinium Retention in the Brain

VIDEO: MRI Gadolinium Contrast Retention in the Brain

Gadolinium May Remain in Brain After Contrast MRI

 

Related Content

Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...
Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...
Shimadzu Medical Systems Receives FDA 510(k) for FluoroSpeed X1 RF System
Technology | Radiographic Fluoroscopy (RF) | August 09, 2019
Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corp., announced they have received U.S. Food and Drug...
Half of Hospital Decision Makers Plan to Invest in AI by 2021
News | Artificial Intelligence | August 08, 2019
August 8, 2019 — A recent study conducted by Olive AI explores how hospital leaders are responding to the imperative
RSNA and ACR to Collaborate on Landmark Medical 3D Printing Registry
News | Medical 3-D Printing | August 08, 2019
The Radiological Society of North America (RSNA) and the American College of Radiology (ACR) will launch a new medical...
ScImage Introduces PICOM ModalityGuard for Cybersecurity
Technology | Cybersecurity | August 07, 2019
ScImage Inc. is bridging the gap between security and functionality with the introduction of the PICOM ModalityGuard....
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...
Canon Medical Introduces Encore Orian MR Upgrade Program
News | Magnetic Resonance Imaging (MRI) | August 06, 2019
Canon Medical Systems USA Inc. is helping to provide low-cost patient care solutions for its customers with the launch...